Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 21, 2021

Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia
Lancet 2021 Feb 02;[EPub Ahead of Print], DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, OV Zubkova, AS Dzharullaeva, AV Kovyrshina, NL Lubenets, DM Grousova, AS Erokhova, AG Botikov, FM Izhaeva, O Popova, TA Ozharovskaya, IB Esmagambetov, IA Favorskaya, DI Zrelkin, DV Voronina, DN Shcherbinin, AS Semikhin, YV Simakova, EA Tokarskaya, DA Egorova, MM Shmarov, NA Nikitenko, VA Gushchin, EA Smolyarchuk, SK Zyryanov, SV Borisevich, BS Naroditsky, AL Gintsburg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading